Nasus Pharma (NSRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.18, +0.47% vs the prior close of $3.16.
- Volume 15.04K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NSRX rises 0.5% to $3.18. Closed at $3.18, +0.47% vs the prior close of $3.16. Day range $3.09–$3.21, opened at $3.09.
NSRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NSRX rises 0.5% to $3.18
- Closed at $3.18, +0.47% vs the prior close of $3.16. Day range $3.09–$3.21, opened at $3.09.
- Volume was 15.04K shares, 0.9x its 50-day average of 16.49K.
- Price is -12.4% vs its 50-day average ($3.63) and -17.4% vs its 200-day average ($3.85).
- 52-week range $1.98–$9.50; today's close sits at 16% of that range, 66.5% below the 52-week high.
Oct 15, 2026 — NSRX dips 0.5% to $3.16
- Closed at $3.16, -0.47% vs the prior close of $3.18. Day range $3.05–$3.22, opened at $3.22.
- Volume was 6.50K shares, 0.4x its 50-day average of 16.76K — lighter than usual.
- Price is -12.9% vs its 50-day average ($3.64) and -18.3% vs its 200-day average ($3.87).
- 52-week range $1.98–$9.50; today's close sits at 16% of that range, 66.7% below the 52-week high.
Oct 14, 2026 — NSRX rises 0.6% to $3.18
- Closed at $3.18, +0.63% vs the prior close of $3.16. Day range $3.08–$3.31, opened at $3.23.
- Volume was 13.30K shares, 0.7x its 50-day average of 17.90K.
- Price is -12.6% vs its 50-day average ($3.64) and -18.4% vs its 200-day average ($3.90).
- 52-week range $1.98–$9.50; today's close sits at 16% of that range, 66.5% below the 52-week high.
Oct 13, 2026 — NSRX slides 4.8% to $3.16, a 1-month low, 7 down days in a row
- Closed at $3.16, -4.82% vs the prior close of $3.32. Day range $3.10–$3.33, opened at $3.22.
- Volume was 13.40K shares, 0.8x its 50-day average of 17.80K.
- Price is -13.3% vs its 50-day average ($3.64) and -19.4% vs its 200-day average ($3.92).
- 52-week range $1.98–$9.50; today's close sits at 16% of that range, 66.7% below the 52-week high.
- That makes 7 straight losses.
Oct 12, 2026 — NSRX slides 5.4% to $3.32, a 1-month low, 6 down days in a row
- Closed at $3.32, -5.41% vs the prior close of $3.51. Day range $3.24–$3.44, opened at $3.33.
- Volume was 30.90K shares, 1.8x its 50-day average of 17.30K.
- Price is -8.9% vs its 50-day average ($3.65) and -15.7% vs its 200-day average ($3.94).
- 52-week range $1.98–$9.50; today's close sits at 18% of that range, 65.1% below the 52-week high.
- That makes 6 straight losses.
Oct 9, 2026 — NSRX slides 3.3% to $3.51, 5 down days in a row
- Closed at $3.51, -3.31% vs the prior close of $3.63. Day range $3.44–$3.66, opened at $3.63.
- Volume was 15.80K shares, 0.9x its 50-day average of 17.03K.
- Price is -3.6% vs its 50-day average ($3.64) and -11.3% vs its 200-day average ($3.96).
- 52-week range $1.98–$9.50; today's close sits at 20% of that range, 63.1% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 — NSRX slides 3.8% to $3.63, 4 down days in a row
- Closed at $3.63, -3.84% vs the prior close of $3.78. Day range $3.50–$3.78, opened at $3.78.
- Volume was 14.00K shares, 0.8x its 50-day average of 17.00K.
- Price is -0.1% vs its 50-day average ($3.63) and -8.7% vs its 200-day average ($3.98).
- 52-week range $1.98–$9.50; today's close sits at 22% of that range, 61.8% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 6-K.
Oct 7, 2026 — NSRX dips 1.7% to $3.78, 3 down days in a row
- Closed at $3.78, -1.69% vs the prior close of $3.84. Day range $3.76–$3.91, opened at $3.86.
- Volume was 9.50K shares, 0.6x its 50-day average of 17.14K — lighter than usual.
- Price is +4.2% vs its 50-day average ($3.62) and -5.5% vs its 200-day average ($4.00).
- 52-week range $1.98–$9.50; today's close sits at 24% of that range, 60.3% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — NSRX ends flat (-0.3%) to $3.84
- Closed at $3.84, -0.26% vs the prior close of $3.85. Day range $3.77–$3.91, opened at $3.88.
- Volume was 17.20K shares, 1.0x its 50-day average of 17.04K.
- Price is +6.4% vs its 50-day average ($3.61) and -4.2% vs its 200-day average ($4.01).
- 52-week range $1.98–$9.50; today's close sits at 25% of that range, 59.6% below the 52-week high.
Oct 5, 2026 — NSRX dips 1.8% to $3.85
- Closed at $3.85, -1.79% vs the prior close of $3.92. Day range $3.80–$4.03, opened at $4.00.
- Volume was 9.60K shares, 0.5x its 50-day average of 17.60K — lighter than usual.
- Price is +7.1% vs its 50-day average ($3.59) and -4.3% vs its 200-day average ($4.02).
- 52-week range $1.98–$9.50; today's close sits at 25% of that range, 59.5% below the 52-week high.
Oct 2, 2026 — NSRX rises 2.8% to $3.92, a 1-month high, 3 up days in a row
- Closed at $3.92, +2.75% vs the prior close of $3.82. Day range $3.79–$4.10, opened at $3.82.
- Volume was 28.70K shares, 1.7x its 50-day average of 17.21K.
- Price is +9.5% vs its 50-day average ($3.58) and -2.9% vs its 200-day average ($4.04).
- 52-week range $1.98–$9.50; today's close sits at 26% of that range, 58.7% below the 52-week high.
- That makes 3 straight gains.
NSRX latest news & SEC filings
Every SEC filing by or about NSRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 23, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 18, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 11, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 4, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 1, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 20, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 19, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 19, 2026 · Form POS AM — POS AM filing
POS AM filing
Aug 17, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Things to know before you trade NSRX
- How much it moves: over the last 20 sessions the average daily move was 2.43% (largest 5.4%).
- Liquidity: about 23.37K shares (≈$74.32K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.18 vs a range of $1.98–$9.50 (16% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 0 sales; latest: Dan Benjamin Teleman bought 6,550 shares on Jun 17, 2026.
- Latest filings: 6-K Oct 8, 2026; 6-K Sep 18, 2026; 6-K Sep 14, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
NSRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.09 | 3.21 | 3.09 | 3.18 | 15.04K |
| Oct 15, 2026 | 3.22 | 3.22 | 3.05 | 3.16 | 6.50K |
| Oct 14, 2026 | 3.23 | 3.31 | 3.08 | 3.18 | 13.30K |
| Oct 13, 2026 | 3.22 | 3.33 | 3.10 | 3.16 | 13.40K |
| Oct 12, 2026 | 3.33 | 3.44 | 3.24 | 3.32 | 30.90K |
| Oct 9, 2026 | 3.63 | 3.66 | 3.44 | 3.51 | 15.80K |
| Oct 8, 2026 | 3.78 | 3.78 | 3.50 | 3.63 | 14.00K |
| Oct 7, 2026 | 3.86 | 3.91 | 3.76 | 3.78 | 9.50K |
| Oct 6, 2026 | 3.88 | 3.91 | 3.77 | 3.84 | 17.20K |
| Oct 5, 2026 | 4.00 | 4.03 | 3.80 | 3.85 | 9.60K |
| Oct 2, 2026 | 3.82 | 4.10 | 3.79 | 3.92 | 28.70K |
| Oct 1, 2026 | 4.00 | 4.01 | 3.76 | 3.82 | 28.60K |
| Sep 30, 2026 | 4.00 | 4.00 | 3.60 | 3.69 | 57.10K |
| Sep 29, 2026 | 3.76 | 3.79 | 3.54 | 3.57 | 34.00K |
| Sep 28, 2026 | 3.69 | 3.78 | 3.35 | 3.59 | 115.10K |
| Sep 25, 2026 | 3.50 | 3.60 | 3.42 | 3.48 | 21.00K |
| Sep 24, 2026 | 3.35 | 3.50 | 3.35 | 3.48 | 3.90K |
| Sep 23, 2026 | 3.57 | 3.79 | 3.50 | 3.64 | 14.90K |
| Sep 22, 2026 | 3.48 | 3.68 | 3.45 | 3.57 | 12.50K |
| Sep 21, 2026 | 3.46 | 3.53 | 3.35 | 3.44 | 6.40K |
About Nasus Pharma
Nasus Pharma (NSRX) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TEL AVIV - YAFO, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 2029039.
NSRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ronnie Hershman | Director | Mar 27, 2026 |
| Isaac Israel | Director | Mar 27, 2026 |
| Dalia Megiddo | Chief Development Officer | Mar 27, 2026 |
| Brendan P. O'Grady | Chief Executive Officer | Jul 31, 2026 |
| Sharon Shacham | Director | Mar 27, 2026 |
| David Silberman | Director | Mar 27, 2026 |
| Dan Benjamin Teleman | Chief Executive Officer | Jul 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Oren Elmaliah | Interim CFO | Sep 23, 2026 |
| Dalia Megiddo | Chief Development Officer | Mar 27, 2026 |
| Brendan P. O'Grady | Chief Executive Officer | Jul 31, 2026 |
| Eyal Rubin | Chief Financial Officer | Sep 21, 2026 |
| Dan Benjamin Teleman | Chief Executive Officer | Jul 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 17, 2026 | Dan Benjamin Teleman | Buy | 6,550 | $3.10 |
| Jun 17, 2026 | Dan Benjamin Teleman | Buy | 6,550 | $3.10 |
| Jun 17, 2026 | Dan Benjamin Teleman | Buy | 6,550 | $3.10 |
| Jun 17, 2026 | Dan Benjamin Teleman | Buy | 6,550 | $3.10 |
| Apr 22, 2026 | Dan Benjamin Teleman | Buy | 2,900 | $3.76 |
| Apr 22, 2026 | Dan Benjamin Teleman | Buy | 2,900 | $3.76 |
| Apr 22, 2026 | Dan Benjamin Teleman | Buy | 2,900 | $3.76 |
| Apr 22, 2026 | Dan Benjamin Teleman | Buy | 2,900 | $3.76 |
| Mar 31, 2026 | Dan Benjamin Teleman | Buy | 15,000 | $2.04 |
| Mar 31, 2026 | Dan Benjamin Teleman | Buy | 15,000 | $2.04 |
| Mar 31, 2026 | Dan Benjamin Teleman | Buy | 15,000 | $2.04 |
| Mar 31, 2026 | Dan Benjamin Teleman | Buy | 15,000 | $2.04 |
NSRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
NSRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NSRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.